ClinicalTrials.gg
RecruitingNCT07334977BrainSpineStimUpdated Jan 12, 2026

Synergistic Effect of Non-invasive Brain and Spinal Cord Stimulation

A Phase 2 interventional study of tDCS and tSCS in Stroke, Spinal Cord Injury and Able Bodied, sponsored by Centre National de la Recherche Scientifique, France. Recruiting at 2 sites in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Centre National de la Recherche Scientifique, France · Phase 2, Interventional, and Supportive care

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Dec 2024, registered Aug 2025).
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 545 studies in Stroke with a site in France — 142 open to participants now, 161 under way, 12 of them phase 3. Stroke · France.

Planned enrollment
218th of 370
45 · median 64
Started
2024
with 31 others
Phase 2
18 of 545
2 open now
Primary completion
2027-07
later than 81 of 160 live
Registered
509th of 545
by date

Among the 545 studies in Stroke with a site in France, this one is the 218th largest by planned enrollment of the 370 interventional ones that give a count, is one of 32 that started in 2024, is one of 18 in phase 2, reaches primary completion later than 81 of the 160 other live ones, and was the 509th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

142 of the 545 studies in Stroke with a site in France are open now. Recruiting first, the newest first:

137 more — sign in →

All 142 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 545 studies in Stroke with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical study is to investigate the potential synergy between non-invasive brain and spinal cord stimulation administered during a cognitive-motor task, in terms of their immediate effects on sensorimotor and cognitive functions after neurological injuries affecting the upper limb (cervical spinal cord injury and stroke). Secondary objectives are to evaluate the relevance of anatomical MRI, functional MRI, and neurophysiological measurements for optimizing and predicting the effects of these different interventions.

Read the detailed description

Over the past decade, innovative electrical stimulation strategies have emerged to improve the effectiveness of conventional rehabilitation approaches following spinal cord injury or stroke. Transcranial direct current stimulation (tDCS) and transcutaneous spinal cord stimulation (tSCS) are two non-invasive stimulation techniques targeting respectively the brain and spinal cord. These techniques have demonstrated immediate and lasting positive effects on the recovery of lost neurological functions following damage to the brain (in the case of stroke) or the spinal cord (in the case of spinal cord injury). Functional improvements leading to a better quality of life have been demonstrated in response to tSCS or tDCS sessions combined with motor training. Recent studies suggest a potential synergistic effect of these two types of intervention, which we propose to characterize in control participants, participants with cervical spinal cord injury, and post-stroke participants.

OBJECTIVES: In this project, we seek to study the potential synergistic effects of an intervention combining non-invasive stimulation of the brain and spinal cord, administered during the performance of a cognitive-motor task, compared to a control intervention and each intervention administered separately, on the recovery of motor and cognitive-motor functions after neurological injury. Secondary objectives are to evaluate the relevance of anatomical MRI data and neurophysiological measurements for optimizing and predicting the effects of these different interventions.

METHODOLOGY/RESEARCH DESIGN: Single-center, prospective, comparative, randomized, crossover, and single-blind clinical study comparing four neuromodulation interventions: S1: tDCS, S2: tSCS, S3: tDCS-tSCS, S4: sham, administered during a cognitive-motor training task of the affected upper limb using the Armeo technology. Three groups of participants will be included: one control group, one group with cervical spinal cord injury, and one post-stroke group. The two groups with either spinal cord injury or stroke will participate in a total of nine visits: the inclusion visit, four testing visits, and four intervention visits. The control group will participate only in the inclusion and testing visits. Outcome measures will include neurophysiological and clinical performance measures.

03

Conditions studied

  • Stroke
  • Spinal Cord Injury
  • Able Bodied

Keywords

  • Neuromodulation
  • Neuroplasticity
  • transcutaneous Spinal Cord Stimulation
  • transcranial Direct Current Stimulation
  • Neuroimaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

CONTROL GROUP:

  • Over 18 years of age
  • Participant who has signed an form
  • Participant who is affiliated with and covered by the social security system

POST-STROKE GROUP:

  • Over 18 years of age
  • Who sustained a stroke more than 3 weeks ago
  • Considered medically stable by the medical investigator
  • Who has signed an informed consent form
  • Affiliated with and covered by the social security system

SCI GROUP:

  • Over 18 years of age
  • Considered to have a complete or incomplete spinal cord injury (i.e., with a score on the Spinal Injury Association (ASIA) Impairment Scale (AIS) score from A to D)
  • Considered medically stable by the investigating physician
  • Presenting with quadriplegia due to cervical injury
  • Who has signed an informed consent form
  • Affiliated with and covered by the social security system.

Exclusion criteria

Exclusion Criteria:

  • Suffering from a chronic condition
  • Skin problems or open wounds
  • History of epilepsy or seizures
  • Presence of a to the use of magnetic/electrical stimulation or MRI, including: cardiac pacemaker; implanted hearing aid; intraocular foreign body, shrapnel, or bullets; metal worker; pacemaker or neurostimulator; claustrophobia
  • Presence of implanted medical devices (cardiac valve, endovascular devices, ventricular shunt valve, surgical clips, metallic sutures, staples, stent, osteosynthesis or arthrodesis hardware) not classified as "MR Conditional" according to ASTM F2503.
  • Individuals who are legally incompetent, under judicial protection, guardianship, or trusteeship
  • Pregnant and/or breastfeeding women
  • Individuals who refuse to be informed of any abnormalities that may be detected by MRI.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    tDCS+CMT

    tDCS administered during the performance of cognitive and motor task for 20 min

    Procedure: tDCS · Behavioral: Cognitive-Motor Task

  • Experimental
    tSCS+CMT

    20-min tSCS administered during the performance of cognitive and motor task for 20 min

    Procedure: tSCS · Procedure: Sham

  • Active comparator
    tDCS-tSCS+CMT

    tDCS associated with tSCS administered during the performance of cognitive and motor task for 20 min

    Procedure: tDCS · Procedure: tSCS · Behavioral: Cognitive-Motor Task

  • Sham comparator
    Sham-tDCS-tSCS+CMT

    Sham tDCS associated with Sham tSCS administered during the performance of cognitive and motor task for 20 min

    Procedure: tDCS · Procedure: tSCS · Procedure: Sham · Behavioral: Cognitive-Motor Task

Interventions

  • ProceduretDCS

    tDCS will be delivered using an electrical stimulation device d (1X1 tES, Soterix Medical Inc., USA, CE marked) delivering a direct current at 2 mA for a period of 20 minutes. Silicone electrodes are placed in sponges soaked in physiological saline (5 cm × 7 cm) (EASYpadTM, Soterix Medical Inc.), with the anode and cathode centered on the optimal cortical areas determined during testing visits.

    Also known as: transcranial Direct Current Stimulation

  • ProceduretSCS

    tSCS will be applied for 20 minutes using a constant current electrical stimulator (DS5 or DS7A, Digitimer Ltd, CE marked) delivering monophasic pulses at 30 Hz at stimulation sites and intensities specific to each participant and defined in advance during testing visits.

    Also known as: transcutaneous Spinal Cord Stimulation

  • ProcedureSham

    For the sham stimulation interventions, the current slowly increases to the intensity used during the active interventions for 30 seconds, then slowly decreases over the next 30 seconds, at the beginning and end of the stimulation. The sham interventions use the same electrode placements as during the active ones for a total duration of 20 min.

  • BehavioralCognitive-Motor Task

    The cognitive-motor task will be administered using the ArmeoControl software supplied with the ArmeoSping® or ArmeoPower® upper limb rehabilitation exoskeleton. Participants will be seated in a chair or their wheelchair and fitted into the exoskeleton.The exoskeleton is linked to a series of exercises performed on a computer via a virtual reality interface (ArmeoControl), which allows simultaneous training of the arms and hands in a large workspace. Two vertical and horizontal "visually guided reaching" tasks will be offered, each lasting 10 minutes. These tasks are chosen to provide training in cognitive-motor functions (grabbing a target moving in a virtual workspace) and sensorimotor functions (interacting with the exoskeleton to move the target).

06

What researchers measure

Primary outcomes

  1. Sensory Performance

    GRASSP subscores: Hand dorsal and palmar sensory function

    Time frame: Immediately post-intervention at interventional visits 1, 2, 3, and 4 (days 14, 18, 21, 25)

  2. Quantitative Prehension Performance

    GRASSP Quantitative Prehension Subscore: Hand prehension motor performance

    Time frame: Immediately post-intervention at interventional visits 1, 2, 3, and 4 (days 14, 18, 21, 25)

Secondary outcomes

  1. Cognitive performance

    Total score on the ECAS multi-domain assessment

    Time frame: Immediately post-intervention at interventional visits 1, 2, 3, and 4 (days 14, 18, 21, 25)

  2. Safety of the intervention

    Safety questionnaire describing side effect appearance and their relative severity. The frequency of a specific side effect will be computed and the severity score (1 to 4) will be averaged across participant

    Time frame: Immediately post-intervention at interventional visits 1, 2, 3, and 4 (days 14, 18, 21, 25)

  3. Feasibility of the intervention

    4-item instrument measuring the feasibility of an intervention. The total score is calculated by summing the four items, yielding a range from 4 to 20, with higher scores indicating greater perceived feasibility of the intervention.

    Time frame: Immediately post-intervention at interventional visits 1, 2, 3, and 4 (days 14, 18, 21, 25)

  4. Neurophysiological assessment of posterior root-muscle reflexes

    Upper-limb electromyographic (EMG) responses during paired-pulse tSCS

    Time frame: Immediately post-intervention at testing visit #2 (day 4)

07

Study locations

2 of 2 sites recruiting
  • Service de Médecine Physique & Réadaptation - CHU Bordeaux
    Bordeaux, 33000, France
    Recruiting
  • Centre de la Tour de Gassies
    Bruges, 33520, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Based on request and on the data type requested and ethically approved (only non-personally Identifiable Information).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jul 2027, 31 months after the start.

Of 112 non-industry phase 2 interventional studies under Stroke, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 31 months is below that.

Counting every sponsor, half of 132 studies reached it within 40 months; a quarter within 24 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Jan 12, 2026
StartActual
Dec 11, 2024
Primary completionEst.
Jul 31, 2027
CompletionEst.
Dec 2027
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07334977
Lead sponsor
Centre National de la Recherche Scientifique, France
Collaborators
University Hospital, Bordeaux, Centre de la Tour de Gassies, Institute of Neurodegenerative Diseases, CNRS UMR 5293
Responsible party
Fabien Wagner (Principal investigator, Centre National de la Recherche Scientifique, France) — Principal investigator
First posted
Jan 12, 2026
Start date
Dec 11, 2024
Primary completion
Jul 31, 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jan 12, 2026

Study contacts

Nabila Brihmat, PhD
Contact
nabila.brihmat@u-bordeaux.fr
+33 5 33 51 48 46
Fabien Wagner, PhD
Contact
fabien.wagner@u-bordeaux.fr
+33 5 33 51 48 46
Fabien Wagner, PhD
principal investigator · Institute of Neurodegenerative Diseases, CNRS UMR 5293
Nabila Brihmat, PhD
principal investigator · Institute of Neurodegenerative Diseases, CNRS UMR 5293
Hélène Cassoudesalle, MD, PhD
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion